Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism

Targeting Bruton's tyrosine kinase (BTK) with the small molecule BTK inhibitor ibrutinib has significantly improved patient outcomes in several B-cell malignancies, with minimal toxicity. Given the reported expression and constitutive activation of BTK in acute myeloid leukemia (AML) cells, the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Rotin, Lianne E., Gronda, Marcela, MacLean, Neil, Hurren, Rose, Wang, XiaoMing, Lin, Feng-Hsu, Wrana, Jeff, Datti, Alessandro, Barber, Dwayne L., Minden, Mark D., Slassi, Malik, Schimmer, Aaron D.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4823070/
https://ncbi.nlm.nih.gov/pubmed/26624983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6409
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares